Octapharma

Missed us at ESID 2026? You can still explore our symposium on secondary immunodeficiency and hear expert perspectives on the burden of SID, infection risk and clinical management. Sign up to the Octapharma Science Hub to discover the symposium content.

Behind the scenes at our Springe production site, our maintenance teams ensure operations run smoothly. Shift Technician Elisei Roman shares how his daily work helps ensure products are manufactured without delays, keeping our production chain moving.

How do new scientific ideas become established therapies? Across haematology, immunotherapy and critical care, our R&D teams apply clinical and scientific expertise to the development of new therapies. Through preclinical and clinical research at our global sites, we work to identify new treatment options and support the safe use of our medicines.

Do you know what goes into making life-saving plasma therapies? From donor to patient, quality is central to how our therapies are made. Through strict standards and regular inspections, we focus on delivering therapies patients can rely on. Swipe to explore our quality control process.

Could miniature antibodies redefine treatment strategies? VHH antibodies, derived from camelids, have the potential to transform treatments across multiple therapeutic fields. These small, specific antibodies can target disease-related proteins. Our Recombinant R&D team is investigating this technology to address unmet medical needs.

Plasma-derived therapies help millions of people globally with life-threatening conditions. These treatments rely entirely on plasma donations. Read why donors like Mike have committed to donating over 1,200 times to help patients in need.